Accelerating Regenerative Medicine

Follow RegMed XB on LinkedIn

  • Upcoming events

    Banner DCVA RegMed XB Community Event

    DCVA & RegMed XB Community Event

    For academic researchers and healthcare innovators interested in valorization, entrepreneurship, and accelerating from lab to patient.

     read more
    Banner AC26

    RegMed XB Annual Conference 2026

    Be part of the 4th RegMed XB Annual Conference: Collaborate to Regenerate. Get inspired and expand your network within the regenerative medicine field.

     read more

  • Expertise

    Business Development & Valorization

    Accelerating Innovation in Regenerative Medicine

     read more

    Research Excellence: Moonshots

    Push the boundaries of research excellence

     read more

    Infrastructure: RegMed XB's Pilot Factory

    A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies

     read more

    Public-Private Entrepreneurship

    Building ecosystems through collaboration

     read more

    Seed Capital

    Secure early-stage funding

     read more

  • Latest news

    Frank Luyten Fast

    Column Frank Luyten: From laboratory to patient: how do we make ATMPs sustainable and accessible?

    We’re proud to share Frank Luyten his reflections in this original column, published by FAST and republished here by RegMed XB with permission.

     read more
    Associate Prof. Françoise Carlotti at the Islet lab of the LUMC

    A Major Advancement for RegMed XB’s Diabetes Moonshot

    As part of RegMed XB’s diabetes moonshot, researchers at the Leiden University Medical Center (LUMC) have developed a method to enhance the purity of insulin-producing islets, grown from stem cells in the laboratory. While originally aimed at diabetes, this technique has broader implications and could be applied to various stem cell-based therapies.

     read more
    Phlox Therapeutics

    Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies

    Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer. 

     read more

  • Moonshots (research excellence)

    Cardiovascular Moonshot

    Regeneration of the human heart

     read more

    Diabetes Moonshot

    A proof-of-concept therapy for Type 1 Diabetes

     read more

    Kidney Moonshot

    The first subunit of a bio-engineered kidney

     read more

    Osteoarthritis Moonshot

    The road to a bio-artificial joint

     read more

  • Pilot Factory (infrastructure)

    The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.

    → Pilot Factory

  • RegMed XB's Ecosystem

    Health Foundations

    The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.

     read more

    Academic Partners

    RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.

     read more

    Industrial Partners

    Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.

     read more

    Governmental Partners

    RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.

     read more

    Life Science & Health partners

    The following Life Science & Health (LSH) partners are collaborate with RegMed XB.

     read more